期刊文献+

地西他滨治疗中危骨髓增生异常综合征2例并文献复习 被引量:1

下载PDF
导出
摘要 DNA过度甲基化是骨髓增生异常综合征(myelodysplasticsyndromes,MDS)的发病原因之一。地西他滨是特异的DNA甲基化转移酶抑制剂。1993年Zagonel等报道小剂量地西他滨15mg/m^2,每次滴注4h,共3天,每4周1个疗程,结果50%患者获血液学改善,40%获完全血液学缓解。此疗效在随后的临床试验中得到进一步肯定。
作者 李倩 郑智茵
出处 《浙江中西医结合杂志》 2013年第12期1022-1024,J0013,共4页 Zhejiang Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献15

二级参考文献59

  • 1陈亚峰,陈钰,王爱华,罗晓鸿,沈志祥.CAG方案治疗骨髓增生异常综合征疗效观察[J].白血病.淋巴瘤,2007,16(1):54-55. 被引量:2
  • 2SorianoA,Chamolin R, Mccormick G, et al. Maintenance therapy with 5 - agacitidine after allogenneic stem all transplantation for acutem ydogenous leukemia and high - risk myelodysplastic syndrome a dese and schedule finding study. Blood, 2005, 108 (1): 104.
  • 3Soriano A, Braitah F, Garcia G, et al. Combination of 5- agacitidine and valproic acid in advanced solid cancers: a phase I study[J]. Proc Asco,2007, 25(8) : 3547.
  • 4Soriano AO, YangH, Faderl S, et al. Safety and caincal activity of the combination of 5 -agacitidine, valproic acid and alltrans retinoic acid in acutemydaid[J]. Blood, 2007, 110(7) : 2302 - 2308.
  • 5Murai M,Toyota M, Satoh A,et al. Aberrant DNA methylation associated with silencing BN IP3 gene expression in haematopoietic tumours [ J ]. Br J Cancer,2005,92 ( 6 ) : 1165-1172.
  • 6van Doom R,Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma:promoter hypennethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73 [ J ]. J Clin Oncol,2005,23 ( 17 ) :3886-3896.
  • 7Hasegawa D,Manabe A,Kubota T. Methylatian status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia[ J]. Br J Haematol,2005,128(6) :805-812.
  • 8Zhang SJ, Endo S, Saito T, et al. Primary malignant lymphoma of the brain:frequent abnormalities and inactivation of p14 tumor suppressor zene[ J]. Cancer Sci ,2005,96 (1) :38-41.
  • 9Santini V, Kantarjian HM,Issa JP. Changes in DNA methylation in neoplasia : pathophysiology and therapeutic implications [ J ]. Ann Intern Med,2001,134(7) :573-586.
  • 10Claus R, Lubbert M. Epigenetie targets in hematopoietic malignancies[J]. Oneogene,2003,22(42) :6489-6496.

共引文献45

同被引文献5

  • 1Yamada K,Furusawa S,Saito K,et al.Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study[J].Leukemia,1995,9:10-14.
  • 2Wei G,Ni W,Ckiao JW,et a1.A recta-analysis of CAG(cytarabme,aclambicin,G-CSF)regimen for the Ireatment of 1029patients with acute myeloid leukemia and myeiodysplastic syndrome[J].J Hematol Oncol,2011,4:46.
  • 3Steensma DP,Baer MR,Slack JL,et al.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes:the alternative dosing for outpatient treatment(ADOPT)trial[J].J Clin Oncol,2009,27:3842-3848.
  • 4Kantarjian H,Issa JP,Rosenfe Id CS.Decitabine improves patient outcomes in mye1odysp Iastic syndromes:resu Its of a phaseⅢrandomized study[J].cancer,2006,106:1794-1803.
  • 5高苏,仇惠英,金正明,唐晓文,傅铮铮,马骁,韩悦,陈苏宁,孙爱宁,吴德沛.地西他滨单药及联合半程和全程CAG方案治疗骨髓增生异常综合征和急性髓系白血病疗效观察[J].中华血液学杂志,2014,35(11):961-965. 被引量:73

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部